Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Vaccines01:30

Cancer Vaccines

433
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
433
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies02:49

Cancer Therapies

7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apadamtase Alfa: First Approval.

Drugs·2024
Same author

Zuranolone: First Approval.

Drugs·2023
Same author

Correction to: Birch Bark Extract: A Review in Epidermolysis Bullosa.

Drugs·2023
Same author

Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.

Drugs·2023
Same author

Birch Bark Extract: A Review in Epidermolysis Bullosa.

Drugs·2023
Same author

Flotufolastat F 18: Diagnostic First Approval.

Molecular diagnosis & therapy·2023
Same journal

Individualized Longitudinal ctDNA Monitoring in Melanoma Using Multiplexed USE-PCR.

Molecular diagnosis & therapy·2026
Same journal

Advances in Gene and Cellular Therapy in Friedreich Ataxia.

Molecular diagnosis & therapy·2026
Same journal

Considering Tumour Sidedness is Critical for Accurate Interpretation of Liquid Biopsy Results in Metastatic Colorectal Cancer.

Molecular diagnosis & therapy·2026
Same journal

Tividenofusp Alfa: First Approval.

Molecular diagnosis & therapy·2026
Same journal

Genetics of Cerebrotendinous Xanthomatosis.

Molecular diagnosis & therapy·2026
Same journal

Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy.

Molecular diagnosis & therapy·2026
See all related articles

Related Experiment Video

Updated: Jul 25, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K

Omidubicel: First Approval.

Young-A Heo1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. mdt@adis.com.

Molecular Diagnosis & Therapy
|June 24, 2023
PubMed
Summary
This summary is machine-generated.

Omidubicel, a novel stem cell graft, has gained FDA approval for treating hematological malignancies. This nicotinamide-modified cord blood therapy aims to reduce infections and speed neutrophil recovery in transplant patients.

More Related Videos

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis
09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

1.3K
Use of the Pyrimidine Analog, 5-Iodo-2′-Deoxyuridine IdU with Cell Cycle Markers to Establish Cell Cycle Phases in a Mass Cytometry Platform
08:37

Use of the Pyrimidine Analog, 5-Iodo-2′-Deoxyuridine IdU with Cell Cycle Markers to Establish Cell Cycle Phases in a Mass Cytometry Platform

Published on: October 22, 2021

3.0K

Related Experiment Videos

Last Updated: Jul 25, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis
09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

1.3K
Use of the Pyrimidine Analog, 5-Iodo-2′-Deoxyuridine IdU with Cell Cycle Markers to Establish Cell Cycle Phases in a Mass Cytometry Platform
08:37

Use of the Pyrimidine Analog, 5-Iodo-2′-Deoxyuridine IdU with Cell Cycle Markers to Establish Cell Cycle Phases in a Mass Cytometry Platform

Published on: October 22, 2021

3.0K

Area of Science:

  • Hematology
  • Stem Cell Transplantation
  • Oncology

Background:

  • Omidubicel is a nicotinamide-modified stem cell graft derived from cord blood.
  • It is developed by Gamida Cell for treating hematological malignancies and hemoglobinopathies.

Purpose of the Study:

  • To summarize the development milestones of omidubicel.
  • To highlight its first FDA approval in April 2023.

Main Methods:

  • Review of omidubicel's development pathway.
  • Summary of clinical data leading to regulatory approval.

Main Results:

  • Omidubicel received its first US FDA approval in April 2023.
  • Approved for adults and children (≥12 years) with hematological malignancies undergoing cord blood transplantation.
  • Indicated to reduce infection incidence and time to neutrophil recovery post-myeloablative conditioning.

Conclusions:

  • Omidubicel represents a significant advancement in stem cell therapy for hematological malignancies.
  • The approval marks a key milestone in making this innovative treatment available to patients.